USAID/Washington through the USAID Mission in Bangladesh has earlier approached SMC to explore the possibility of introducing the Sayana® Press injectable in Bangladesh. Sayana® Press is a subcutaneous injection prefilled with 104 mg of depot medroxyprogesterone acetate, popularly known as DMPA. This product contains 30 percent less DMPA than the intramuscular presentation, but a woman can safely switch between both formulations/presentations. This product comes packaged in a Uniject device for subcutaneous injection.

Each unit of Sayana® Press is intended for a single use and comes packaged in a sealed foil pouch (primary packaging). Sayana® Press is a registered trademark of Pfizer, Inc. Since it is prefilled, it does not require a clinical setting for administration. The primary advantages of Sayana® Press for the healthcare provider include the fact that the injection is pre-filled, and Sayana® Press as a subcutaneous injection is easier to administer.